Autoimmune Diseases  >>  Epratucyn (epratuzumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Epratucyn (epratuzumab) / Gilead
NCT00383214 / 2005-000706-31: Study of Epratuzumab in Systemic Lupus Erythematosus (SLE)

Checkmark ALLEVIATE; SL0006
Nov 2013 - Nov 2013: ALLEVIATE; SL0006
Checkmark ALLEVIATE
Apr 2013 - Apr 2013: ALLEVIATE
Checkmark P3 data: ALLEVIATE, Moderate to severe active lupus
More
Terminated
3
54
US, Canada, Europe, RoW
Epratuzumab, Placebo
UCB Pharma
Systemic Lupus Erythematosus
03/07
03/07
NCT00111306 / 2005-000705-59: Study of Epratuzumab in Systemic Lupus Erythematosus

Checkmark ALLEVIATE; SL0006
Nov 2013 - Nov 2013: ALLEVIATE; SL0006
Checkmark ALLEVIATE
Apr 2013 - Apr 2013: ALLEVIATE
Checkmark P3 data: ALLEVIATE, Moderate to severe active lupus
More
Terminated
3
510
US, Europe
epratuzumab
UCB Pharma
Systemic Lupus Erythematosus
03/07
03/07
NCT00382837: Study of Epratuzumab in Systemic Lupus Erythematosus

Withdrawn
3
0
US, Canada, Europe, RoW
Epratuzumab
UCB Pharma
Systemic Lupus Erythematosus
 
 
EMBODY 1, NCT01262365 / 2010-018563-41: Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus

Checkmark SLE
Jan 2015 - Jul 2015: SLE
Completed
3
793
US, Europe, RoW
Epratuzumab, Placebo
UCB Pharma
Systemic Lupus Erythematosus
05/15
05/15
EMBODY4, NCT01408576 / 2010-020859-30: Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus

Completed
3
1250
Canada, US, Europe, RoW
Epratuzumab
UCB Pharma
Systemic Lupus Erythematosus
02/16
02/16

Download Options